BioLight Life Sciences to Present at 26th Annual ROTH Conference

BioLight Life Sciences to Present at 26th Annual ROTH Conference

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE BioLight Life Sciences Investments Ltd

TEL AVIV, Israel, February 27, 2014 /PRNewswire/ --

BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY, TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that Suzana Nahum-Zilberberg, chief executive officer, will present at the 26th Annual ROTH Conference on Monday, March 10, 2014 at 9:30 a.m. Pacific time.  Ms. Nahum-Zilberberg will provide an overview of BioLight's business and growth strategy.  The presentation will be webcast live and a link to the audio and slides will be posted in the Investor Relations section of BioLight website http://www.bio-light.co.il/202306/Overview. A replay will be available on the company's website for 365 days.

The conference is being held at the Ritz Carlton, Laguna Niguel in Dana Point, Calif. from March 9 through March 12.

About BioLight

BioLight Life Sciences Investments (OTC: BLGTY, TASE: BOLT), invests in, manages and commercializes biomedical innovations grouped into "clusters" around defined medical conditions. The two current clusters are in ophthalmology via 100% ownership of XLVision Sciences, and in cancer diagnostics via a 29% controlling ownership of Micromedic (TASE: MCTC). XLVision technologies include IOPtimate™, a laser-based noninvasive surgical treatment for glaucoma; TeaRx, a point-of-care dry-eye syndrome diagnostic test; and Eye-D™, a long-term controlled release drug-delivery implant platform. Micromedic diagnostic tests are designated for colorectal, cervical, breast, bladder, lung and other cancers.

For more information please visit the Company's website at http://www.bio-light.co.il

CONTACTS:

BioLight
Itai Bar-Natan, CFO (itai@bio-light.co.il)
Tel: +972-73-2753400


LHA
Kim Sutton Golodetz (kgolodetz@lhai.com)
(212)838-3777
Or
Bruce Voss (bvoss@lhai.com)
(310)691-7100


©2012 PR Newswire. All Rights Reserved.